Aubrey de Grey describes his plan to get combinations of promising aging damage-repair approaches. Aging is accumulated molecular and cellular damage from metabolism, leading to pathology. He emphasizes that we already know enough to pursue preventative maintenance on the body, which is like maintaining a car for longevity. He highlights progress in startups addressing all …
A primary focus of LEV Foundation’s work is to empirically demonstrate the feasibility and value of the divide-and-conquer approach to treating age-related disease – that is, the simultaneous deployment of therapies that independently address the distinct classes of damage that accumulate in aging bodies. With a steadily increasing number of such therapies now showing benefits …
Dr. Aubrey de Grey discusses his Robust Mouse Rejuvenation (RMR) studies at the LEV Foundation. He believes that three more RMR (Robust Mouse Rejuvenation) studies of combination therapy will get us to the goal of adding an average 12 months of lifespan to a 2 year old mouse that would normally be expected to live …
Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did have additive benefits. Combination treatments worked together to improve the lengthening of lifespans. Rapamycin is the strongest main confirmed antiaging treatment. His group is setting up a second experiment with new combination treatments but will …
Donations from Didier Coeurnelle enable next phase of LEVF (Longevity escape velocity foundation) Robust Mouse Rejuvenation research program. The initial donation of €200,000 (approximately $220,000) will be increased by a further €200,000 donations to LEVF during the month of October 2024 will be doubled. Donate to LEVF in the next 10 days to boost antiaging …
Regulators such as the FDA do not consider aging to be a disease, and they only approve treatments for specific diseases, largely using the World Health Organization’s International Classification of Diseases as the basis for what is and is not a disease. The TAME (Targeting Aging with Metformin) trial came into being as a way …
Mitochondrial dysfunction is implicated in dozens of age- related diseases, including Alzheimer’s, retinal disease, liver dysfunction, immune senescence, and more. Mitrix Bio has pioneered a new way of addressing these diseases, using young bioreactor-grown mitochondria encased in vesicles, which they call Mitlets. Mitochondrial energy declines as we age, causing a wide array of chronic diseases. …
George Church spoke at Aubrey de Grey’s conference to discuss using gene editing to provide radical life extension. George is hopeful that gene editing can be used to realize longevity escape velocity. Longevity escape velocity is where we add one year of life extension to people life in less than one year. If Longevity escape …
Inhibition of IL-11 signalling extends mammalian healthspan and lifespan- Nature Female Il11-deleted mice are protected from age-associated obesity, frailty, and metabolic decline. Male mice lives 22.5% longer and female mice 25% longer. The effects were similar to rapamycin but had less negative effects on liver and other organs when rapamycin is used for extended times. …
Two years ago, Nextbigfuture highlighted Maia Biotechnology, which might have the most promising treatment for all cancers. They poison cells that express the telomerase enzyme which indicates cancerous activity. The drug treatment is called Thio. 90% of cancers express telomerase enzyme. Brian Wang interviewed Antiaging expert Aubrey de Grey. Aubrey told Nextbigfuture that his favorite …
Two longevity (antiaging) nonprofits – SENS Research Foundation and Lifespan.io (Lifespan Extension Advocacy Foundation) – have unveiled plans to merge, upon completion of regulatory approvals. Founded in 2009, SENS Research Foundation, has funded cutting-edge research into the science of aging and regenerative medicine. Lifespan.io is a dynamic hub for advancing the frontier of longevity research. …